Increased Risk of Heart Failure in Elderly Patients Treated with Beta-Blockers After AV Node Ablation

Introduction: Controversy exists regarding the indication of beta-blockers (BB) in different scenarios in patients with cardiovascular disease. We sought to evaluate the effect of BB on survival and heart failure (HF) hospitalizations in a sample of pacemaker-dependent patients after AV node ablatio...

Descripción completa

Detalles Bibliográficos
Autores: Bertomeu-Gonzalez, V., Moreno-Arribas, J., Heras, S., Fernandez-Ortiz, N., Cazorla, D., Quintanilla, M.A., Lopez-Ayala, J.M., Facila, L., Zuazola, P., Cordero, Alberto
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/21633
Acceso en línea:https://portalcientifico.sergas.gal//documentos/63df0a766fdec82c4e7deaf6
http://hdl.handle.net/20.500.11940/21633
Access Level:acceso abierto
Palabra clave:Humans
Aged
Retrospective Studies
Atrioventricular Node
Heart Failure
Adrenergic beta-Antagonists
Heart Rate
Hospitalization
AS Santiago
IDIS
Descripción
Sumario:Introduction: Controversy exists regarding the indication of beta-blockers (BB) in different scenarios in patients with cardiovascular disease. We sought to evaluate the effect of BB on survival and heart failure (HF) hospitalizations in a sample of pacemaker-dependent patients after AV node ablation to control ventricular rate for atrial tachyarrhythmias. Methods: A retrospective study including consecutive patients that underwent AV node ablation was conducted in a single center between 2011 and 2019. The study's primary endpoints were the incidence of all-cause mortality, first HF hospitalization and the cumulative incidence of subsequent hospitalizations for HF. Competing risk analyses were employed. Results: A total of 111 patients with a mean age of 73.9 years were included in the study. After a median follow-up of 45.5 months, 43 patients had died (38.7%) and 31 had been hospitalized for HF (27.9%). The recurrent HF hospitalization rate was 74/1000 patients/year. Patients treated with BB had a non-significant trend to higher mortality rates and a higher risk of recurrent HF hospitalizations (incidence rate ratio 2.23, 95% confidence interval 1.12-4.44; p = 0.023). Conclusion: After an AV node ablation, the use of BB is associated with an increased risk of HF hospitalizations in a cohort of elderly patients.